However, feedback activation of EGFR upon BRAF blockade in BRAFmut CRC cells [13] results in a minimal response to selective BRAF inhibitors with only 5% of patients responding, compared to an 80% response rate in BRAFV600E melanoma patients [37]. This evidence concerns the gene EGFR and melanoma.